Therefore, ACE inhibitors (ACEi) and AT1 receptor blockers (ARBs) have been used as first-line therapies to reduce the progression of chronic kidney diseases (CKD) [3], [6]. This evidence concerns the gene AGTR1 and chronic kidney disease.